Panavance Therapeutics Highlights Phase 1 Clinical Trial Insights
Misetionamide combined with gemcitabine shows a good safety profile and potential effectiveness in treating pancreatic cancer.
Interim analysis reveals approximately 40% of participants achieved either a partial response or stable disease.
The ongoing Phase 1 dose-selection trial is expected to conclude in the coming years.
Overview
Panavance Therapeutics Inc., a clinical-stage pharmaceutical company dedicated to innovative oncology treatments, has shared interim findings from its Phase 1 clinical trial of misetionamide (GP-2250) in conjunction with gemcitabine. This announcement was made at a significant medical conference where fresh insights into the drug’s efficacy against pancreatic ductal adenocarcinoma (PDAC) were presented.
Profile of the Clinical Trial
The Phase 1 trial, featuring an open-label and single-arm design, is focused on patients suffering from advanced or metastatic PDAC. These patients have previously undergone first-line therapy with 5FU-based regimens like FOLFIRINOX. The study aims to explore safety, tolerability, and preliminary effectiveness, with 49 patients included across 11 cohorts thus far.
Notably, the findings reveal a reassuring safety profile; no grade ?3 adverse events have been documented during initial monotherapy. When combining misetionamide with gemcitabine, there have been some serious events—five classified as grade 3 and 10 as grade 4—though these were clearly linked to gemcitabine, with only one possibly traceable to misetionamide.
Comparative Effectiveness
Initial results indicate that patients receiving the misetionamide-gemcitabine blend experience enhanced progression-free survival compared to historical data for gemcitabine alone. Among the study participants, six have shown partial responses with tumor reductions surpassing 30%, including one patient who has remained in the study for over two years.
Expert Commentary on Progress
Dr. Anup Kasi, a key investigator from the University of Kansas Cancer Center, provided detailed insights at the conference on the trial’s progress. He highlighted that approximately 40% of patients exhibit either a partial response or stable disease, affirming the potential of the misetionamide-gemcitabine combination against historical benchmarks. He expressed optimism regarding the drug's efficacy and safety profile.
Future Directions for Panavance
In light of the positive interim results, Panavance Therapeutics is excited about the next phases of the trial. CEO Greg Bosch emphasized the company's commitment to completing the Phase 1 study, which involves four US clinical sites. Bosch indicated upcoming trials, including efforts against platinum-resistant ovarian cancer and as a first-line maintenance treatment for non-BRCA mutated pancreatic cancer patients, are in the pipeline.
About Misetionamide
Misetionamide stands out as a small molecule with a unique capacity to inhibit two vital oncogenic transcription factors: c-MYC and NF?B. Its mechanism of action disrupts cancer cell energy metabolism, leading to cell death, while also inhibiting proliferation and survival. This points to misetionamide's potential as a selective agent against various tumor types, paving the road for further studies.
Conclusion
As Panavance Therapeutics charts a path forward, the promising initial outcomes from the Phase 1 study bolster confidence in misetionamide’s potential. With detailed focus on patient safety and therapeutic outcomes, the company is poised to make significant contributions to cancer treatment and patient care
Frequently Asked Questions
What is the purpose of the Phase 1 clinical trial?
The trial aims to evaluate the safety, tolerability, and preliminary effectiveness of misetionamide combined with gemcitabine in treating advanced pancreatic cancer.
How many participants are involved in the trial?
Currently, the trial has enrolled 49 patients across 11 cohorts.
What are the key findings reported?
Interim findings suggest around 40% of patients achieved either a partial response or stable disease during the trial.
Who is leading the trial?
Dr. Anup Kasi, an Associate Professor at the University of Kansas Cancer Center, is the primary investigator for this clinical trial.
What are the future plans for misetionamide?
Panavance plans to initiate additional trials targeting other cancer types, expanding its research on misetionamide's potential efficacy beyond pancreatic cancer.
